Long-term_follow-up_and_prognostic_factor_analysis_in_advanced_ovarian_carcinoma:_the_Gynecologic_Oncology_Group_experience._Long-term_follow-up_was_obtained_on_726_women_with_advanced_ovarian_carcinoma_(suboptimal_stage_III_and_stage_IV)_who_had_received_primary_chemotherapy_on_two_Gynecologic_Oncology_Group_(GOG)_protocols_between_1976_and_1982._The_first_study_compared_melphalan_alone_versus_melphalan_plus_hexamethylmelamine_versus_cyclophosphamide_plus_doxorubicin_(CA)._The_second_study_evaluated_the_same_CA_regimen_with_or_without_cisplatin._Eligibility_for_the_two_studies_was_the_same._At_last_contact,_76_patients_were_alive._In_a_multivariate_analysis,_cell_type_other_than_clear_cell_or_mucinous,_cisplatin-based_treatment,_good_performance_status,_younger_age,_lower_stage,_clinically_nonmeasurable_disease,_smaller_residual_tumor_volume,_and_absence_of_ascites_were_favorable_characteristics_for_overall_survival_(P_less_than_.05)._Second-look_laparotomy_was_negative_significantly_more_often_among_those_with_endometrioid_tumors;_there_were_no_negative_second-look_laparotomies_among_those_with_mucinous_or_clear_cell_tumors._There_were_30_patients_with_suboptimal_stage_III_disease_who_had_a_negative_second-look_laparotomy;_18_(60%)_have_experienced_recurrence,_and_13_(43%)_have_died._Although_cisplatin_treatment_was_beneficial,_new_treatments_are_clearly_needed.